Association between serum levels of soluble tumor necrosis factor receptors/CA 125 and disease progression in patients with epithelial ovarian malignancy
BACKGROUND A prospective study was undertaken within the Gynecologic Oncology Group to determine whether serum levels of soluble tumor necrosis factor receptors I (sTNFR‐I) and II (sTNFR‐II), alone or in combination with CA 125, were associated with clinicopathologic characteristics or outcome in pa...
Gespeichert in:
| Veröffentlicht in: | Cancer 2004-07, Vol.101 (1), p.106-115 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 115 |
|---|---|
| container_issue | 1 |
| container_start_page | 106 |
| container_title | Cancer |
| container_volume | 101 |
| creator | Burger, Robert A. Darcy, Kathleen M. DiSaia, Philip J. Monk, Bradley J. Grosen, Elizabeth A. Gatanaga, Tetsuya Granger, Gale A. Wang, Jianmin Tian, Chunqiao Hanjani, Parviz Cohn, David E. |
| description | BACKGROUND
A prospective study was undertaken within the Gynecologic Oncology Group to determine whether serum levels of soluble tumor necrosis factor receptors I (sTNFR‐I) and II (sTNFR‐II), alone or in combination with CA 125, were associated with clinicopathologic characteristics or outcome in patients with epithelial ovarian malignancies.
METHODS
Quantitative immunoassays were performed on valid pretreatment serum specimens obtained from patients with epithelial ovarian malignancies to assess levels of sTNFR‐I, sTNFR‐II, and CA 125. The authors then analyzed the results of these immunoassays for potential correlations with clinicopathologic characteristics and outcome.
RESULTS
The median age of the 139 women evaluated was 59 years. Seventy‐eight percent had Stage III or IV disease, and 58% had serous carcinomas. sTNFR‐II was associated with age (P = 0.013), and CA 125 was associated with histologic subtype (P = 0.0009). In addition, sTNFR‐I (P = 0.037) and CA 125 (P < 0.0001) were associated with extent of disease. After adjusting for patient age, histologic subtype, and extent of disease, all three biomarkers were predictive of progression‐free survival, but not overall survival, when the combination was included in the model. The authors observed a 51% reduction (hazard ratio [HR], 0.49; 95% confidence interval [CI], 0.24–0.99), a 2.9‐fold increase (HR, 2.87; 95% CI, 1.15–7.20), and a 22% increase (HR, 1.22; 95% CI, 0.99–1.51) in the risk of progression for each unit increase in the log‐transformed levels of sTNFR‐I, sTNFR‐II, and CA 125, respectively.
CONCLUSIONS
The observations made in the current study—that among patients with low or high CA 125 levels, those with high sTNFR‐I levels and low sTNFR‐II levels had the lowest risk, that patients with low‐low or high‐high sTNFR‐I and sTNFR‐II levels, respectively, had an intermediate risk, and that patients with low sTNFR‐I levels and high sTNFR‐II levels had the highest risk of progression—suggested the potential value of simultaneous assessment of all three biomarkers in patients with epithelial ovarian malignancies. Cancer 2004. © 2004 American Cancer Society.
A prospective serum biomarker study was undertaken to determine the association of serum levels of soluble tumor necrosis factor receptors I (sTNFR‐I) and II (sTNFR‐II), alone or in association with CA 125, with clinical characteristics and outcomes in patients with epithelial ovarian malignancies. Results suggest that distinct relationships |
| doi_str_mv | 10.1002/cncr.20314 |
| format | Article |
| fullrecord | <record><control><sourceid>wiley</sourceid><recordid>TN_cdi_wiley_primary_10_1002_cncr_20314_CNCR20314</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>CNCR20314</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1194-985b65d0e174a8de57749535112aee7d77a411ef6343e27efdc2afc4412404a53</originalsourceid><addsrcrecordid>eNotkMtKAzEYhYMoWKsbn-B_gam5Np1lGbxBURAFd0Oa-adGMsmQTFv6KL6t0-rmXDbnwEfILaMzRim_s8GmGaeCyTMyYbTUBWWSn5MJpXRRKCk-L8lVzt9j1VyJCflZ5hytM4OLAdY47BEDZEzbDjzu0GeILeTot2uPMGy7mCCgTTG7DK2xw9gTWuzHkO-qJTCuwIQGGpfRZIQ-xU3CnI_zLkA_HmEYMuzd8AXYj4reGQ9xZ5IzATrj3SaYYA_X5KI1PuPNv0_Jx8P9e_VUrF4fn6vlqrCMlbIoF2o9Vw1FpqVZNKi0lqUSijFuEHWjtZGMYTsXUiDX2DaWm9ZKybik0igxJexvd-88Huo-uc6kQ81ofSRaH4nWJ6J19VK9nZL4BTDZb3E</addsrcrecordid><sourcetype>Publisher</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Association between serum levels of soluble tumor necrosis factor receptors/CA 125 and disease progression in patients with epithelial ovarian malignancy</title><source>Wiley Online Library Journals Frontfile Complete</source><source>Wiley Online Library Free Content</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Burger, Robert A. ; Darcy, Kathleen M. ; DiSaia, Philip J. ; Monk, Bradley J. ; Grosen, Elizabeth A. ; Gatanaga, Tetsuya ; Granger, Gale A. ; Wang, Jianmin ; Tian, Chunqiao ; Hanjani, Parviz ; Cohn, David E.</creator><creatorcontrib>Burger, Robert A. ; Darcy, Kathleen M. ; DiSaia, Philip J. ; Monk, Bradley J. ; Grosen, Elizabeth A. ; Gatanaga, Tetsuya ; Granger, Gale A. ; Wang, Jianmin ; Tian, Chunqiao ; Hanjani, Parviz ; Cohn, David E.</creatorcontrib><description>BACKGROUND
A prospective study was undertaken within the Gynecologic Oncology Group to determine whether serum levels of soluble tumor necrosis factor receptors I (sTNFR‐I) and II (sTNFR‐II), alone or in combination with CA 125, were associated with clinicopathologic characteristics or outcome in patients with epithelial ovarian malignancies.
METHODS
Quantitative immunoassays were performed on valid pretreatment serum specimens obtained from patients with epithelial ovarian malignancies to assess levels of sTNFR‐I, sTNFR‐II, and CA 125. The authors then analyzed the results of these immunoassays for potential correlations with clinicopathologic characteristics and outcome.
RESULTS
The median age of the 139 women evaluated was 59 years. Seventy‐eight percent had Stage III or IV disease, and 58% had serous carcinomas. sTNFR‐II was associated with age (P = 0.013), and CA 125 was associated with histologic subtype (P = 0.0009). In addition, sTNFR‐I (P = 0.037) and CA 125 (P < 0.0001) were associated with extent of disease. After adjusting for patient age, histologic subtype, and extent of disease, all three biomarkers were predictive of progression‐free survival, but not overall survival, when the combination was included in the model. The authors observed a 51% reduction (hazard ratio [HR], 0.49; 95% confidence interval [CI], 0.24–0.99), a 2.9‐fold increase (HR, 2.87; 95% CI, 1.15–7.20), and a 22% increase (HR, 1.22; 95% CI, 0.99–1.51) in the risk of progression for each unit increase in the log‐transformed levels of sTNFR‐I, sTNFR‐II, and CA 125, respectively.
CONCLUSIONS
The observations made in the current study—that among patients with low or high CA 125 levels, those with high sTNFR‐I levels and low sTNFR‐II levels had the lowest risk, that patients with low‐low or high‐high sTNFR‐I and sTNFR‐II levels, respectively, had an intermediate risk, and that patients with low sTNFR‐I levels and high sTNFR‐II levels had the highest risk of progression—suggested the potential value of simultaneous assessment of all three biomarkers in patients with epithelial ovarian malignancies. Cancer 2004. © 2004 American Cancer Society.
A prospective serum biomarker study was undertaken to determine the association of serum levels of soluble tumor necrosis factor receptors I (sTNFR‐I) and II (sTNFR‐II), alone or in association with CA 125, with clinical characteristics and outcomes in patients with epithelial ovarian malignancies. Results suggest that distinct relationships exist between pretreatment serum levels of sTNFR‐I or sTNFR‐II compared with CA 125 and historically important clinicopathologic variables. This study also provides compelling evidence of a more refined risk assessment model for ovarian cancer progression when serum concentrations of all three biomarkers are simultaneously included in Cox regression analyses.</description><identifier>ISSN: 0008-543X</identifier><identifier>EISSN: 1097-0142</identifier><identifier>DOI: 10.1002/cncr.20314</identifier><language>eng</language><publisher>Hoboken: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>biomarkers ; CA 125 ; ovarian carcinoma ; soluble tumor necrosis factor receptor I ; soluble tumor necrosis factor receptor II</subject><ispartof>Cancer, 2004-07, Vol.101 (1), p.106-115</ispartof><rights>Copyright © 2004 American Cancer Society</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c1194-985b65d0e174a8de57749535112aee7d77a411ef6343e27efdc2afc4412404a53</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fcncr.20314$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fcncr.20314$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,1427,27903,27904,45553,45554,46388,46812</link.rule.ids></links><search><creatorcontrib>Burger, Robert A.</creatorcontrib><creatorcontrib>Darcy, Kathleen M.</creatorcontrib><creatorcontrib>DiSaia, Philip J.</creatorcontrib><creatorcontrib>Monk, Bradley J.</creatorcontrib><creatorcontrib>Grosen, Elizabeth A.</creatorcontrib><creatorcontrib>Gatanaga, Tetsuya</creatorcontrib><creatorcontrib>Granger, Gale A.</creatorcontrib><creatorcontrib>Wang, Jianmin</creatorcontrib><creatorcontrib>Tian, Chunqiao</creatorcontrib><creatorcontrib>Hanjani, Parviz</creatorcontrib><creatorcontrib>Cohn, David E.</creatorcontrib><title>Association between serum levels of soluble tumor necrosis factor receptors/CA 125 and disease progression in patients with epithelial ovarian malignancy</title><title>Cancer</title><description>BACKGROUND
A prospective study was undertaken within the Gynecologic Oncology Group to determine whether serum levels of soluble tumor necrosis factor receptors I (sTNFR‐I) and II (sTNFR‐II), alone or in combination with CA 125, were associated with clinicopathologic characteristics or outcome in patients with epithelial ovarian malignancies.
METHODS
Quantitative immunoassays were performed on valid pretreatment serum specimens obtained from patients with epithelial ovarian malignancies to assess levels of sTNFR‐I, sTNFR‐II, and CA 125. The authors then analyzed the results of these immunoassays for potential correlations with clinicopathologic characteristics and outcome.
RESULTS
The median age of the 139 women evaluated was 59 years. Seventy‐eight percent had Stage III or IV disease, and 58% had serous carcinomas. sTNFR‐II was associated with age (P = 0.013), and CA 125 was associated with histologic subtype (P = 0.0009). In addition, sTNFR‐I (P = 0.037) and CA 125 (P < 0.0001) were associated with extent of disease. After adjusting for patient age, histologic subtype, and extent of disease, all three biomarkers were predictive of progression‐free survival, but not overall survival, when the combination was included in the model. The authors observed a 51% reduction (hazard ratio [HR], 0.49; 95% confidence interval [CI], 0.24–0.99), a 2.9‐fold increase (HR, 2.87; 95% CI, 1.15–7.20), and a 22% increase (HR, 1.22; 95% CI, 0.99–1.51) in the risk of progression for each unit increase in the log‐transformed levels of sTNFR‐I, sTNFR‐II, and CA 125, respectively.
CONCLUSIONS
The observations made in the current study—that among patients with low or high CA 125 levels, those with high sTNFR‐I levels and low sTNFR‐II levels had the lowest risk, that patients with low‐low or high‐high sTNFR‐I and sTNFR‐II levels, respectively, had an intermediate risk, and that patients with low sTNFR‐I levels and high sTNFR‐II levels had the highest risk of progression—suggested the potential value of simultaneous assessment of all three biomarkers in patients with epithelial ovarian malignancies. Cancer 2004. © 2004 American Cancer Society.
A prospective serum biomarker study was undertaken to determine the association of serum levels of soluble tumor necrosis factor receptors I (sTNFR‐I) and II (sTNFR‐II), alone or in association with CA 125, with clinical characteristics and outcomes in patients with epithelial ovarian malignancies. Results suggest that distinct relationships exist between pretreatment serum levels of sTNFR‐I or sTNFR‐II compared with CA 125 and historically important clinicopathologic variables. This study also provides compelling evidence of a more refined risk assessment model for ovarian cancer progression when serum concentrations of all three biomarkers are simultaneously included in Cox regression analyses.</description><subject>biomarkers</subject><subject>CA 125</subject><subject>ovarian carcinoma</subject><subject>soluble tumor necrosis factor receptor I</subject><subject>soluble tumor necrosis factor receptor II</subject><issn>0008-543X</issn><issn>1097-0142</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid/><recordid>eNotkMtKAzEYhYMoWKsbn-B_gam5Np1lGbxBURAFd0Oa-adGMsmQTFv6KL6t0-rmXDbnwEfILaMzRim_s8GmGaeCyTMyYbTUBWWSn5MJpXRRKCk-L8lVzt9j1VyJCflZ5hytM4OLAdY47BEDZEzbDjzu0GeILeTot2uPMGy7mCCgTTG7DK2xw9gTWuzHkO-qJTCuwIQGGpfRZIQ-xU3CnI_zLkA_HmEYMuzd8AXYj4reGQ9xZ5IzATrj3SaYYA_X5KI1PuPNv0_Jx8P9e_VUrF4fn6vlqrCMlbIoF2o9Vw1FpqVZNKi0lqUSijFuEHWjtZGMYTsXUiDX2DaWm9ZKybik0igxJexvd-88Huo-uc6kQ81ofSRaH4nWJ6J19VK9nZL4BTDZb3E</recordid><startdate>20040701</startdate><enddate>20040701</enddate><creator>Burger, Robert A.</creator><creator>Darcy, Kathleen M.</creator><creator>DiSaia, Philip J.</creator><creator>Monk, Bradley J.</creator><creator>Grosen, Elizabeth A.</creator><creator>Gatanaga, Tetsuya</creator><creator>Granger, Gale A.</creator><creator>Wang, Jianmin</creator><creator>Tian, Chunqiao</creator><creator>Hanjani, Parviz</creator><creator>Cohn, David E.</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><scope/></search><sort><creationdate>20040701</creationdate><title>Association between serum levels of soluble tumor necrosis factor receptors/CA 125 and disease progression in patients with epithelial ovarian malignancy</title><author>Burger, Robert A. ; Darcy, Kathleen M. ; DiSaia, Philip J. ; Monk, Bradley J. ; Grosen, Elizabeth A. ; Gatanaga, Tetsuya ; Granger, Gale A. ; Wang, Jianmin ; Tian, Chunqiao ; Hanjani, Parviz ; Cohn, David E.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1194-985b65d0e174a8de57749535112aee7d77a411ef6343e27efdc2afc4412404a53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>biomarkers</topic><topic>CA 125</topic><topic>ovarian carcinoma</topic><topic>soluble tumor necrosis factor receptor I</topic><topic>soluble tumor necrosis factor receptor II</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Burger, Robert A.</creatorcontrib><creatorcontrib>Darcy, Kathleen M.</creatorcontrib><creatorcontrib>DiSaia, Philip J.</creatorcontrib><creatorcontrib>Monk, Bradley J.</creatorcontrib><creatorcontrib>Grosen, Elizabeth A.</creatorcontrib><creatorcontrib>Gatanaga, Tetsuya</creatorcontrib><creatorcontrib>Granger, Gale A.</creatorcontrib><creatorcontrib>Wang, Jianmin</creatorcontrib><creatorcontrib>Tian, Chunqiao</creatorcontrib><creatorcontrib>Hanjani, Parviz</creatorcontrib><creatorcontrib>Cohn, David E.</creatorcontrib><jtitle>Cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Burger, Robert A.</au><au>Darcy, Kathleen M.</au><au>DiSaia, Philip J.</au><au>Monk, Bradley J.</au><au>Grosen, Elizabeth A.</au><au>Gatanaga, Tetsuya</au><au>Granger, Gale A.</au><au>Wang, Jianmin</au><au>Tian, Chunqiao</au><au>Hanjani, Parviz</au><au>Cohn, David E.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Association between serum levels of soluble tumor necrosis factor receptors/CA 125 and disease progression in patients with epithelial ovarian malignancy</atitle><jtitle>Cancer</jtitle><date>2004-07-01</date><risdate>2004</risdate><volume>101</volume><issue>1</issue><spage>106</spage><epage>115</epage><pages>106-115</pages><issn>0008-543X</issn><eissn>1097-0142</eissn><abstract>BACKGROUND
A prospective study was undertaken within the Gynecologic Oncology Group to determine whether serum levels of soluble tumor necrosis factor receptors I (sTNFR‐I) and II (sTNFR‐II), alone or in combination with CA 125, were associated with clinicopathologic characteristics or outcome in patients with epithelial ovarian malignancies.
METHODS
Quantitative immunoassays were performed on valid pretreatment serum specimens obtained from patients with epithelial ovarian malignancies to assess levels of sTNFR‐I, sTNFR‐II, and CA 125. The authors then analyzed the results of these immunoassays for potential correlations with clinicopathologic characteristics and outcome.
RESULTS
The median age of the 139 women evaluated was 59 years. Seventy‐eight percent had Stage III or IV disease, and 58% had serous carcinomas. sTNFR‐II was associated with age (P = 0.013), and CA 125 was associated with histologic subtype (P = 0.0009). In addition, sTNFR‐I (P = 0.037) and CA 125 (P < 0.0001) were associated with extent of disease. After adjusting for patient age, histologic subtype, and extent of disease, all three biomarkers were predictive of progression‐free survival, but not overall survival, when the combination was included in the model. The authors observed a 51% reduction (hazard ratio [HR], 0.49; 95% confidence interval [CI], 0.24–0.99), a 2.9‐fold increase (HR, 2.87; 95% CI, 1.15–7.20), and a 22% increase (HR, 1.22; 95% CI, 0.99–1.51) in the risk of progression for each unit increase in the log‐transformed levels of sTNFR‐I, sTNFR‐II, and CA 125, respectively.
CONCLUSIONS
The observations made in the current study—that among patients with low or high CA 125 levels, those with high sTNFR‐I levels and low sTNFR‐II levels had the lowest risk, that patients with low‐low or high‐high sTNFR‐I and sTNFR‐II levels, respectively, had an intermediate risk, and that patients with low sTNFR‐I levels and high sTNFR‐II levels had the highest risk of progression—suggested the potential value of simultaneous assessment of all three biomarkers in patients with epithelial ovarian malignancies. Cancer 2004. © 2004 American Cancer Society.
A prospective serum biomarker study was undertaken to determine the association of serum levels of soluble tumor necrosis factor receptors I (sTNFR‐I) and II (sTNFR‐II), alone or in association with CA 125, with clinical characteristics and outcomes in patients with epithelial ovarian malignancies. Results suggest that distinct relationships exist between pretreatment serum levels of sTNFR‐I or sTNFR‐II compared with CA 125 and historically important clinicopathologic variables. This study also provides compelling evidence of a more refined risk assessment model for ovarian cancer progression when serum concentrations of all three biomarkers are simultaneously included in Cox regression analyses.</abstract><cop>Hoboken</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><doi>10.1002/cncr.20314</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0008-543X |
| ispartof | Cancer, 2004-07, Vol.101 (1), p.106-115 |
| issn | 0008-543X 1097-0142 |
| language | eng |
| recordid | cdi_wiley_primary_10_1002_cncr_20314_CNCR20314 |
| source | Wiley Online Library Journals Frontfile Complete; Wiley Online Library Free Content; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | biomarkers CA 125 ovarian carcinoma soluble tumor necrosis factor receptor I soluble tumor necrosis factor receptor II |
| title | Association between serum levels of soluble tumor necrosis factor receptors/CA 125 and disease progression in patients with epithelial ovarian malignancy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T11%3A11%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wiley&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Association%20between%20serum%20levels%20of%20soluble%20tumor%20necrosis%20factor%20receptors/CA%20125%20and%20disease%20progression%20in%20patients%20with%20epithelial%20ovarian%20malignancy&rft.jtitle=Cancer&rft.au=Burger,%20Robert%20A.&rft.date=2004-07-01&rft.volume=101&rft.issue=1&rft.spage=106&rft.epage=115&rft.pages=106-115&rft.issn=0008-543X&rft.eissn=1097-0142&rft_id=info:doi/10.1002/cncr.20314&rft_dat=%3Cwiley%3ECNCR20314%3C/wiley%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |